AVAX Technologies' M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma

Data Gathered from a Larger Patient Population with Ten-Year Follow-Up Consistent with Previously Reported Data
New Findings Suggest Improved Survival Even After Patient Relapse
Data Presented at the Annual Meeting of the American Society of Clinical Oncology

AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO)(May 20-23) in New Orleans on the company's autologous cell vaccine (AC Vaccine™) M-Vax™ for the treatment of metastatic melanoma. The data from additional studies confirm and expand the results of a study published in 1997 showing that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence.

The trials, which began in 1989, include 214 patients. All had melanoma with large (at least 3 cm diameter) regional lymph node metastases. Following removal of the lymph node masses, patients were treated with M-Vax by one of four dosage-schedules. The median follow-up time for these patients is 4.4 years, and the longest is over 10 years. Fifty-four patients have been observed for five years or more. M-Vax caused no major side effects.

The overall five-year survival rate from all these trials for patients with spread of melanoma to one nodal area was 50%, versus historical five-year survival rates of approximately 20-25% for patients treated with surgery alone. Of note, this group included high-risk patients with clinical features usually associated with poor prognosis, such as in-transit metastases, tumor masses that spread to the skin between the primary site and the lymph node. Another high-risk group treated in this study included patients with spread of melanoma to two nodal areas. In this group, the five-year survival was 35%, versus a 10% five-year survival rate when patients are treated with lymph node surgery alone.

A second major finding of

Contact: Sue Yeoh
201-641-2408 ext. 43
AVAX Technologies, Inc.

Page: 1 2 3

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
3. AVAX Technologies AC Vaccine™ improves relapse-free survival
4. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:

(Date:6/19/2020)... ... June 18, 2020 , ... ... series, “Automate Your Lab with Software for Data Decisions,” for pharmaceutical and ... how to integrate and automate cutting-edge scientific instruments and laboratory equipment from ...
(Date:6/5/2020)... ... ... Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq ... Next Generation Genomic Sequencing (NGS) . This is the third application filed by SimplSeq ... “I have been at the bench for over 20 years,” stated Brandon Young, CTO ...
(Date:5/28/2020)... ... ... CrucialTrak, a global designer and manufacturer of biometric access control systems, today announced that ... its complete line of biometric readers and access gates . CEG is a ... , Brett Mason, CrucialTrak’s Director of Channel Sales for the Americas is very excited ...
Breaking Biology News(10 mins):
(Date:6/2/2020)... SPRINGFIELD, Ill. (PRWEB) , ... June 01, 2020 ... ... a helping hand to companies and encourage positive change in the world, enterprise ... the coronavirus pandemic. , With more people working from home during self-quarantines and ...
(Date:5/28/2020)... ... May 28, 2020 , ... Genedata, the leading ... Genedata Screener ® 17.0, the latest version of its enterprise software for ... assay technologies. Genedata will host a webinar on June 10, 2020, detailing and ...
(Date:5/21/2020)... ... May 21, 2020 , ... Threats to intellectual property, political ... Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical ... from the pandemic commercially weaker, dealing with delays in new product launches and ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... Simon Prakash, who will serve as the company’s executive vice president of product ... when Exo is disrupting the medical imaging space, bringing more than 24 years ...
Breaking Biology Technology:
Cached News: